SCHEMBL31108290

SCHEMBL31108290

Cc1c(NC(=O)c2ccc(CNCCNC(=O)CCCN)cn2)cccc1-c1cccc(NC(=O)c2ccc(CN3CC4(CCOCC4)C3)cn2)c1Cl

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PDCD1 Q15116 20/20 0.51
▸ CD274 Q9NZQ7 20/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31108255 0.90 PDCD1 (0.47) PDCD1CD274
SCHEMBL31108349 0.88 PDCD1 (0.53) PDCD1CD274
SCHEMBL31108278 0.86 PDCD1 (0.52) PDCD1CD274
SCHEMBL31108260 0.84 PDCD1 (0.60) PDCD1CD274
SCHEMBL31108337 0.83 PDCD1 (0.51) PDCD1CD274
SCHEMBL31108319 0.81 CD274 (0.60) PDCD1CD274
SCHEMBL31108320 0.81 PDCD1 (0.55) PDCD1CD274
SCHEMBL31108272 0.81 PDCD1 (0.53) PDCD1CD274
SCHEMBL31108335 0.81 PDCD1 (0.52) PDCD1CD274
SCHEMBL31108306 0.79 PDCD1 (0.52) PDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4694981-A1 HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS Aurigene Oncology Limited (IN) 2026-02-18 — — EP disclosed
WO-2024214088-A1 HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS AURIGENE ONCOLOGY LIMITED (IN) 2024-10-17 — — WO disclosed
Send feedback